Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
-2.69%-5.28%+58.42%+65.89% 68.45B
-0.90%+7.60%+14.18%+90.78% 61.31B
-0.27%+0.33%+20.45%+98.33% 55.73B
-0.31%+2.13%+12.83%+109.02% 47.51B
-2.04%-2.26%+18.85%+37.19% 44.68B
-3.01%-11.24%+165.09%+768.52% 38.14B
+2.15%-0.47%+22.85%+56.09% 35.85B
-2.69%-2.58%+74.90%+52.17% 33.05B
-0.37%+3.10%-38.23%+393.51% 25.9B
Average -0.53%+2.41%+38.82%+185.72% 46B
Weighted average by Cap. -1.27%+2.25%+39.11%+159.85%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-